Physician-Supervised Peptide Program
Cellular Longevity Peptide Program
A supervised longevity track — mitochondrial-focused peptides considered inside a lab-guided plan.
A physician-supervised longevity-focused peptide program at EBO2 Therapy and Wellness. Every element — whether any peptide is considered, and which one — is directed by the supervising physician after consultation and baseline labs.
Quick answer
A physician-supervised longevity-focused peptide program at EBO2 Therapy and Wellness. Every element — whether any peptide is considered, and which one — is directed by the supervising physician after consultation and baseline labs. A supervised longevity track — mitochondrial-focused peptides considered inside a lab-guided plan.
Program Overview
A supervised program, not an off-the-shelf product
The Cellular Longevity Peptide Program is built for clients who want a lab-guided, physician-directed approach to longevity support rather than a self-managed stack. Longevity, in this context, is about mitochondrial health, sleep quality, exercise tolerance, and how your body handles recovery — not a promise of extended lifespan.
Consultation and labs come first. Only after the supervising physician has reviewed your goals, history, medications, and baseline biomarkers is any peptide considered. If a peptide is added, it is because the physician has judged it appropriate to consider inside your specific plan.
This program pairs naturally with our broader cellular optimization work — including the CTOI cellular optimization report — but it never replaces medical care from your primary or specialty providers.
Who It's Considered For
- Adults focused on long-arc wellness who want a physician-directed plan rather than a self-directed stack
- Clients who want longevity decisions grounded in labs and follow-up
- Concierge patients pairing longevity peptides with EBO3, NAD+, HBOT, or Red Light on the physician's guidance
- Individuals who understand peptides are one adjunct inside a broader wellness plan
Medical Oversight
Physician-directed from consultation onward
A supervising physician at EBO2 Therapy and Wellness owns each decision inside the longevity track: which biomarkers to test, whether a peptide fits, cadence, and follow-up. Nothing about the program is transactional — the physician can pause or discontinue any component based on labs and response.
Options a Physician May Consider
Peptides studied inside this category
Depending on your labs and physician review, the following longevity-adjacent peptides may be considered. These are options the physician may consider, not a purchase list.
SS-31
A mitochondrial-targeted peptide researched for cardiolipin interactions and mitochondrial membrane support. Any consideration is at physician discretion after screening.
MOTS-C
A mitochondrial-derived peptide studied for metabolic and exercise-tolerance signaling. Whether it is appropriate for you is a physician decision.
Epitalon
A short peptide researched in the context of circadian and pineal signaling. Consideration and cadence, if any, are determined by the supervising physician after labs.
Listing here is educational only. Availability of any specific peptide, and whether it is appropriate for you, is determined by the supervising physician after consultation and labs. No outcome is promised, and no FDA approval is claimed for any wellness protocol.
How the Program Starts
Consult → labs → individualized plan
Step 1
Consultation
Private intake and physician review — goals, medical history, current medications, prior labs, sleep, and training inputs.
Step 2
Baseline biomarkers
Labs ordered before any peptide is considered. Results anchor the physician's plan and every future adjustment.
Step 3
Individualized plan
Physician determines whether a peptide is appropriate, which category, and at what cadence. Lifestyle inputs are part of the plan.
Step 4
Follow-up
Interval labs and reviews on the physician's cadence — adjustments, pauses, and discontinuations happen based on how you respond.
Program length: Longevity work is a long game. Programs are typically structured in physician-directed cycles with follow-up biomarkers, then reassessed. There is no fixed end date — cadence and duration are decided by your supervising physician based on labs and response.
Safety & Oversight
Non-negotiables of the program
- Baseline and interval labs are required — no peptide is added on assumption.
- The physician alone determines what is used, at what cadence, and when to pause or stop.
- Pregnancy, breastfeeding, active cancer, and certain conditions or medications may exclude or modify options.
- Any new symptom is reviewed with the clinical team before the next dose.
- The program supports — but does not replace — medical care from your primary or specialty providers.
No FDA approval is claimed for any wellness protocol. No specific longevity outcome or lifespan extension is promised.
What Programs Cost
Discussed at consultation
Program pricing is discussed at consultation and depends on the physician's plan, labs cadence, and program length. Pricing reflects a supervised program — not a product purchase — so it is set at the individualized-plan level.
Related Peptide Programs
Explore other physician-supervised tracks
Weight Management Program
Physician-supervised GLP-1 and advanced options reviewed after labs.
Learn more →
Recovery Program
Soft-tissue and post-effort recovery peptides considered under supervision.
Learn more →
Energy & Vitality Program
Physician-guided peptides for energy, sleep quality, and daily vitality.
Learn more →
FAQ
Common Questions About the Cellular Longevity Peptide Program
Who is a candidate for the Cellular Longevity Program?
How does the program start?
How long does the program run?
How is safety monitored?
What does the program cost?
Does this program promise longevity outcomes?
Begin Your Journey
Ask about the Cellular Longevity Peptide Program
Programs start with a private consultation, labs, and a physician-directed plan — not a checkout.
Available at our clinics
Peptide Therapy in California & Florida
Explore peptide therapy at each EBO2 Therapy and Wellness location, or dig into a side-by-side comparison and the clinical guide.
Medically reviewed by Daniel Moghadam, MD.
Page updated: July 2026
This page is maintained by EBO2 Therapy and Wellness to answer common questions about Cellular Longevity Peptide Program. Content is educational and is not a substitute for consultation, screening, and provider guidance. See the full Medical Disclaimer at the end of this page.
How candidacy for Cellular Longevity Peptide Program is evaluated
- Medical history, current medications, and prior labs are reviewed at consultation.
- Baseline labs are ordered before any peptide program is started.
- Pregnancy, breastfeeding, active cancer, and certain conditions may exclude or modify options.
- Selection of any specific peptide, dose, and cadence is entirely at physician discretion.
- Peptide programs are wellness-focused and are not a substitute for medical care; results vary.
Screening, history, and provider guidance determine whether any protocol is appropriate for a given individual. Results vary.
Where this information comes from
FDA approvals for GLP-1 products such as WEGOVY are specific to a particular product, route, dose, and indication and do NOT transfer to compounded semaglutide, unapproved GLP-1 formulations, or investigational peptide stacks (e.g. BPC-157, MOTS-c, TB-500). FDA has flagged dosing errors with compounded semaglutide and safety risks with several bulk peptide substances. Programs at EBO2 remain physician-supervised.
- WEGOVY (semaglutide) — FDA prescribing label
DailyMed (U.S. National Library of Medicine)
Current FDA-approved prescribing information for WEGOVY, defining approved indication, dosing, route, and safety information. Approval is product/route/indication-specific.
- FDA alerts providers, compounders, and patients to dosing errors with compounded semaglutide
U.S. Food & Drug Administration
FDA safety alert on dosing errors associated with compounded semaglutide. Regulatory/safety context only; does not endorse compounded products.
- FDA intends to take action against non-FDA-approved GLP-1 drugs
U.S. Food & Drug Administration
FDA statement on planned enforcement against non-FDA-approved GLP-1 products. Regulatory context; not a recommendation for any specific program.
- FDA — Certain Bulk Drug Substances Used to Compound Drug Products May Present Significant Safety Risks
U.S. Food & Drug Administration
FDA safety-risk framing for bulk drug substances used in compounding — the category that covers BPC-157, MOTS-c, TB-500, and related investigational peptides. Risk/regulatory context only.
- FDA — Unapproved Drugs enforcement policy overview
U.S. Food & Drug Administration
FDA overview of how the agency treats drugs that lack FDA approval, providing regulatory context for compounded and unapproved products.
References describe general evidence, safety, or regulatory context. They do not establish an individual benefit for any specific person, and they do not validate EBO2's proprietary clinic protocols.